: The clinical management of small cell lung cancer (SCLC) treatment remains a major challenge for thoracic oncologists, with very few therapeutic advances significantly impacting patients' survival. The recent introduction of immunotherapy in the clinical setting produced a marginal benefit for a limited subset of metastatic patients, while the therapeutic scenario for relapsing extended-disease small cell lung cancers (ED-SCLCs) remains almost deserted. Recent efforts clarified the molecular features of this disease, leading to the identification of key signalling pathways which may serve as potential targets for clinical use. Despite the large number of molecules tested and the numerous therapeutic failures, some targeted therapies have recently shown interesting preliminary results. In this review, we describe the main molecular pathways involved in SCLC development/progression and provide an updated summary of the targeted therapies currently under investigation in SCLC patients.

Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies

Cani, Massimiliano;Napoli, Valerio Maria;Garbo, Edoardo;Ferrari, Giorgia;Del Rio, Benedetta;Novello, Silvia;Passiglia, Francesco
2023-01-01

Abstract

: The clinical management of small cell lung cancer (SCLC) treatment remains a major challenge for thoracic oncologists, with very few therapeutic advances significantly impacting patients' survival. The recent introduction of immunotherapy in the clinical setting produced a marginal benefit for a limited subset of metastatic patients, while the therapeutic scenario for relapsing extended-disease small cell lung cancers (ED-SCLCs) remains almost deserted. Recent efforts clarified the molecular features of this disease, leading to the identification of key signalling pathways which may serve as potential targets for clinical use. Despite the large number of molecules tested and the numerous therapeutic failures, some targeted therapies have recently shown interesting preliminary results. In this review, we describe the main molecular pathways involved in SCLC development/progression and provide an updated summary of the targeted therapies currently under investigation in SCLC patients.
2023
May 17;24
10
1
22
SCLC; small cell lung cancer; targeted therapies
Cani, Massimiliano; Napoli, Valerio Maria; Garbo, Edoardo; Ferrari, Giorgia; Del Rio, Benedetta; Novello, Silvia; Passiglia, Francesco
File in questo prodotto:
File Dimensione Formato  
ijms-24-08883.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 881.54 kB
Formato Adobe PDF
881.54 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1906610
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact